Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma

W Fukuokaya, T Yanagisawa, M Hashimoto… - Cancer Immunology …, 2023 - Springer
Background The KEYNOTE-045 trial showed that pembrolizumab therapy improved the
survival of patients with advanced urothelial carcinoma (UC). However, its effectiveness in …
被引用次数：5 相关文章

Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma.

W Fukuokaya, T Yanagisawa, M Hashimoto… - Cancer Immunology …, 2022 - europepmc.org
Background The KEYNOTE-045 trial showed that pembrolizumab therapy improved the
survival of patients with advanced urothelial carcinoma (UC). However, its effectiveness in …

Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma

W Fukuokaya, T Yanagisawa, M Hashimoto… - 2022 - researchsquare.com
Background The KEYNOTE-045 trial showed that pembrolizumab therapy improved the
survival of patients with advanced urothelial carcinoma (UC). However, its effectiveness in …

Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma

W Fukuokaya, T Yanagisawa… - Cancer Immunology …, 2023 - search.proquest.com
Background The KEYNOTE-045 trial showed that pembrolizumab therapy improved the
survival of patients with advanced urothelial carcinoma (UC). However, its effectiveness in …

Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma.

W Fukuokaya, T Yanagisawa… - Cancer Immunology …, 2023 - search.ebscohost.com
Background: The KEYNOTE-045 trial showed that pembrolizumab therapy improved the
survival of patients with advanced urothelial carcinoma (UC). However, its effectiveness in …

Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma

W Fukuokaya, T Yanagisawa… - Cancer …, 2023 - pubmed.ncbi.nlm.nih.gov
Background The KEYNOTE-045 trial showed that pembrolizumab therapy improved the
survival of patients with advanced urothelial carcinoma (UC). However, its effectiveness in …
[HTML] nih.gov

[HTML][HTML] Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma

W Fukuokaya, T Yanagisawa… - Cancer Immunology …, 2023 - ncbi.nlm.nih.gov
Background The KEYNOTE-045 trial showed that pembrolizumab therapy improved the
survival of patients with advanced urothelial carcinoma (UC). However, its effectiveness in …

Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma.

W Fukuokaya, T Yanagisawa, M Hashimoto… - Cancer Immunology …, 2022 - europepmc.org
Background The KEYNOTE-045 trial showed that pembrolizumab therapy improved the
survival of patients with advanced urothelial carcinoma (UC). However, its effectiveness in …